A recombinant, fully human, monoclonal neutralizing antibody against COVID-19 entered the phase-1 clinical trial as it was injected into the first subject on Sunday in Shanghai. The clinical trial of the antibody was approved by the National Medical Products Administration on Friday.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3